Phio Pharmaceuticals Corp.
PHIO
$1.09
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 8.53M | 6.53M | 4.62M | 4.13M | 3.59M |
| Gross Profit | -8.53M | -6.53M | -4.62M | -4.13M | -3.59M |
| SG&A Expenses | 4.94M | 4.99M | 4.60M | 4.23M | 3.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.47M | 11.52M | 9.22M | 8.36M | 7.45M |
| Operating Income | -13.47M | -11.52M | -9.22M | -8.36M | -7.45M |
| Income Before Tax | -12.90M | -10.93M | -8.70M | -7.95M | -7.09M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.90 | -10.93 | -8.70 | -7.95 | -7.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.90M | -10.93M | -8.70M | -7.95M | -7.09M |
| EBIT | -13.47M | -11.52M | -9.22M | -8.36M | -7.45M |
| EBITDA | -13.47M | -11.51M | -9.22M | -8.36M | -7.44M |
| EPS Basic | -1.39 | -1.49 | -1.55 | -2.73 | -3.83 |
| Normalized Basic EPS | -0.87 | -0.93 | -0.97 | -1.71 | -2.39 |
| EPS Diluted | -1.39 | -1.49 | -1.55 | -2.73 | -3.83 |
| Normalized Diluted EPS | -0.87 | -0.93 | -0.97 | -1.71 | -2.39 |
| Average Basic Shares Outstanding | 38.06M | 31.24M | 23.93M | 15.71M | 11.23M |
| Average Diluted Shares Outstanding | 38.06M | 31.24M | 23.93M | 15.71M | 11.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |